long intergenic non-protein coding RNA 1492Genealiases: []
Q-omics provides the consensus-scored LINC01492 profile across patient tissues and cancer cell-line models. LINC01492 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC01492 is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, LINC01492 RNA expression shows 6,666 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, HNSC, and STAD as cancer lineages where LINC01492 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01492 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01492 survival associations across molecular data types. LINC01492 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01492 RNA expression–survival associations across cancer types. High LINC01492 expression shows unfavorable associations in KIRC, KICH, PAAD and ESCA, but favorable associations in LUSC and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC01492 RNA expression.
This table summarizes LINC01492 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01492. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01492 shows higher tumor expression in HNSC and LUSC. The HNSC box plot shows higher LINC01492 RNA expression in tumor versus normal tissue (log2 FC = +0.014, t-test p = .007).
This table shows molecular features associated with LINC01492 in patient tissues and cancer cell lines. In patient samples, LINC01492 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
